Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, has today announced the appointment of Zeus Capital Limited as joint broker with immediate effect. About Avacta Group plc – https://www.avacta.com

Dr Alastair Smith leads a Yorkshire-based drug developer which is striving to find treatments for a wide range of cancers, writes Deputy Business Editor Greg Wright. It cannot claim to

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that it will be holding a shareholder update evening and presentation on Wednesday, 22 April 2020 at

While diagnostic test makers have come to rely on antibodies for test development – a whole class of tests, immunodiagnostics, are based on antibodies – issues around them have been

A published paper in Biotechniques from the laboratory of Dr Darren Tomlinson at the University of Leeds, UK, demonstrates key characteristics exhibited by Affimer reagents in capturing target proteins from complex matrices

Immunotherapy can: Educate the immune system to recognize and attack specific cancer cells Boost immune cells to help them eliminate cancer Provide the body with additional components to enhance the

Alastair Smith provides overview of pre|CISIONTM prodrug technology and update on AVA6000 clinical trial Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its financial results for the 17 months ended 31 December 2019 on Tuesday, 21 April 2020. An analyst briefing given